key: cord-0769876-k7xvccn0 authors: Gualano, Bruno; Ribeiro Lemes, Italo; Pires da Silva, Rafael; Pinto, Ana J.; Mazzolani, Bruna C.; Smaira, Fabiana I.; Sieczkowska, Sofia M.; Aikawa, Nadia E.; Pasoto, Sandra G.; Medeiros-Ribeiro, Ana C.; G. S. Saad, Carla; F. N. Yuk, Emily; Silva, Clovis A.; Swinton, Paul; Hallal, Pedro C.; Roschel, Hamilton; Bonfa, Eloisa title: Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases date: 2021-12-23 journal: Brain Behav Immun DOI: 10.1016/j.bbi.2021.12.016 sha: 4bf3cff290f3a980a3b692b6e705639c881291fa doc_id: 769876 cord_uid: k7xvccn0 OBJECTIVES: To investigate whether physical activity is associated with enhanced immunogenicity of a SARS-CoV-2 inactivated vaccine (Coronavac) in patients with autoimmune rheumatic diseases (ARD) (n=898) and in non-ARD (n=197) individuals without pre-existing immunogenicity to SARS-CoV-2. METHODS: This was a prospective cohort study within an open-label, single-arm, phase 4 vaccination trial. Immunogenicity was assessed after vaccination by measuring seroconversion rates of total anti-SARS-CoV-2 S1/S2 IgG (SC), geometric mean titers of anti-S1/S2 IgG (GMT), factor-increase in GMT (FI-GMT), frequency of neutralizing antibody (NAb), and median neutralizing activity. Physical activity (active being defined as ≥150 min/week) and sedentary behavior (>8 h/day) were assessed by questionnaire. RESULTS: Physically active ARD patients (n=494) were younger and more frequently used prednisone/biologics than inactive patients (n=404). After controlling for covariates, active patients exhibited greater SC (OR: 1.4 [95%CI: 1.1-2.0]), GMT (32% [95%CI: 8.8-60) and FI-GMT (33% [95%CI: 9.6-63%]) vs. inactive. Cluster analysis (physical activity/sedentary status) revealed greater GMT (43.0% [95% CI: 11.0-84.0%) and FI-GMT (48.0% [95%CI: 14.0-92.0%]) in active/non-sedentary vs. inactive/sedentary ARD patients. A dose-response was observed, with greater benefits for the group of patients performing ≥350 min/week of physical activity (OR: 1.6 [95%CI: 1.1-2.4]; 41% [95%CI: 10-80%]; 35% [95%CI: 4.3-74], for SC, GMT, and FI-GMT, respectively) vs. the least active group (≤30 min/week). Greater SC (OR: 9.9 [95%CI: 1.1-89.0]) and GMT (26% [95%CI: 2.2-56.0%]) were observed in active vs. inactive non-ARD. CONCLUSIONS: A physically active lifestyle may enhance SARS-CoV-2 vaccine immunogenicity, a finding of particular clinical relevance for immunocompromised patients. Trial Registration: Clinicaltrials.gov #NCT04754698 inactive non-ARD. A physically active lifestyle may enhance SARS-CoV-2 vaccine immunogenicity, a finding of particular clinical relevance for immunocompromised patients. Trial Registration: Clinicaltrials.gov #NCT04754698 Vaccines have played a vital role in controlling the COVID-19 pandemic, as observed in countries well-advanced in rolling out vaccination. [1] [2] [3] However, a concern remains that vaccine-induced immunogenicity might not be as high in immunocompromised individuals, such as those with autoimmune rheumatic diseases (ARD), neoplasia, and transplant recipients. In a small study involving patients with chronic inflammatory diseases (n=26), all patients developed antibody responses after SARS-CoV-2 mRNA vaccination, but they exhibited reduced IgG and neutralizing antibodies levels compared to healthy controls. 4 In addition, a reduced anti-spike antibody response was showed after the 1 st (17%) and 2 nd doses (54%) of SARS-CoV-2 mRNA 1273 or BNT162b2 vaccine in solid organ transplant recipients. 5, 6 In a retrospective cohort study of patients with a variety of immune-mediated inflammatory diseases including ARD (n=84), 91% produced detectable neutralizing activity to BNT162b2 mRNA SARS-CoV-2 vaccine. 7 Furthermore, a non-controlled, prospective cohort study with ARD patients (n=123) showed presence of anti-receptor-binding domain (RBD) antibodies in 74% of them, but lower IgG and neutralizing antibody levels compared to healthy controls 8 . In line with this finding, we recently showed that an inactivated virus vaccine against SARS-CoV-2 (CoronaVac, the most frequently administered vaccine worldwide) elicited a lower but still clinically effective response in a large cohort of patients with ARD (n=910) compared to controls. 9 Although the impact of this reduced immunogenicity (i.e., the type of immune responses that the vaccine generates and their magnitude over time) upon vaccine effectiveness (i.e., the vaccine's ability to prevent disease in the real world) remains unknown, efforts to determine modifiable factors potentially able to enhance vaccine response are of utmost importance, particularly in immunocompromised individuals. Regular physical activity reduces chronic low-grade inflammation and has been linked to increased T-cell proliferation and cytokine production following antigenic stimulation, increased neutrophil phagocytic activity, and increased natural killer cell cytolytic activity. 10 There is also evidence that physical activity can improve immune responses to influenza and pneumococcal vaccines, hastening the recovery following experimental rhinovirus infection. 10 A recent meta-analysis from 6 studies involving 497 individuals vaccinated against H1N1, H3N2, influenza type-B, pneumococcal and varicella zoster virus showed that pooled antibody concentration after vaccination is higher with an adjunct physical activity program, leading to the speculation that physical activity may "strengthen the potency of immunization programs and help mitigate the impact of pandemics such as the COVID-19". 11 To our knowledge, this is the first study to investigate the influence of physical activity on the immunogenicity of CoronaVac in a large cohort of patients with ARD. As a secondary objective, we also assessed whether physical activity status affects immunogenicity in non-ARD individuals. Our working hypothesis was that physically active ARD patients would experience better vaccine-induced immune responses compared to their inactive peers. The protocol was approved by the National and Institutional Ethical Committee of the Hospital das Clínicas. Written informed consent was obtained from each participant before enrollment. This was a prospective cohort study within the protocol of an open-label, single-arm, phase 4 vaccination trial (clinicaltrials.gov #NCT04754698), conducted at a tertiary referral hospital in Sao Paulo, Brazil. ARD patients aged ≥18 years and diagnosed with rheumatoid arthritis, systemic lupus erythematosus, axial spondyloarthritis, psoriatic arthritis, primary vasculitis, primary Sjögren's syndrome, systemic sclerosis, systemic autoimmune myopathies and primary antiphospholipid syndrome, following previously reported criteria. 9 Additionally, a group of individuals without ARD, HIV or other conditions requiring immunosuppressive therapy were also studied. Exclusion criteria were: history of anaphylactic response to vaccine components, acute febrile illness or symptoms compatible to COVID-19 at vaccination, Guillain-Barré syndrome, decompensated heart failure (class III or IV), demyelinating disease, previous vaccination with any SARS-CoV-2 vaccine, history of live virus vaccine up to four weeks before, inactivated virus vaccine up to two weeks before, and receipt of blood products up to six months before the study, hospitalized patients, and pre-vaccination COVID-19 assessed by anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies (NAb). Participants who had RT-PCR-confirmed COVID-19 after receiving 1 st vaccine dose were excluded. 9 Participants underwent a two-dose schedule of CoronaVac (Sinovac Life Sciences, Beijing, China, batch #20200412) as previously described. 9 The 1 st dose was administered on February 9-10, 2021 (D0) and the 2 nd dose was given on March 9-10, 2021 (D28). Blood samples (20mL) from all participants were obtained at D0, D28, and D69 (six weeks after 2 nd dose) at the Hospital Convention Center. Sera were stored in a -70 ºC freezer for posterior analysis. Participants were asked how many days/week and minutes/day were spent in moderate-to-vigorous intensity activities in each domain, and summed for total time spent in moderate-to-vigorous physical activity. Participants were classified as physically active or inactive according to WHO Guidelines (i.e., physical inactivity defined as <150 min/week of moderate-to-vigorous intensity aerobic activity). 12 Sedentary behavior was assessed by asking participants how many hours/day were spent sitting throughout the week and weekend days. Sedentary status (yes: ≥8 hours/day; or no: <8 hours/day) 13 was used in combination with physical activity to test whether these would additively influence the outcomes. Six telephone calls and text messages were made to each participant before deeming the individual as a non-respondent. Immunogenicity was assessed at D69 using seroconversion rates of total anti-SARS-CoV-2 S1/S2 IgG (SC), geometric mean titers of anti-S1/S2 IgG (GMT) and their factor-increase in GMT (FI-GMT), frequency of NAb and median (interquartile range) of neutralizing activity. Human IgG antibodies against S1 and S2 proteins in RBD (Indirect ELISA, LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin, Italy) were assessed by chemiluminescent immunoassay. SC was defined as positive serology (>15.0 UA/mL) post vaccination (considering all participants were negative for pre-vaccination serology at baseline). GMT was calculated attributing 1.9 UA/mL (half of the lower limit of quantification) to undetectable levels (<3.8 UA/mL). FI-GMT was determined as the ratio between GMT after and before vaccination and are presented as geometric means and 95% confidence intervals (CIs). Circulating NAb against SARS-CoV-2 was assessed using the SARS-CoV-2 sVNT Kit (GenScript, Piscataway, NJ, USA), which detects neutralizing antibodies that block the interaction between RBD in the viral spike glycoprotein with angiotensin-converting enzyme 2 (ACE2) cell surface receptor. Tests were performed on ETI-MAX-3000 (DiaSorin, Italy). Samples were classified as either "positive" or "negative" (inhibition ≥30 or <30%, respectively), as suggested by the manufacturer. Median (interquartile range) of the percentage of neutralizing activity was calculated for positive samples. Baseline characteristics and outcomes for both ARD patients and non-ARD individuals measured after vaccination were compared across activity levels using 2 test for categorical variables, exact test for categorical variables with a count <5, and the Kruskal-Wallis test for continuous variables. Model-based analyses were then performed controlling for age (<60 or ≥60 years), sex, and BMI (<25 kg/m 2 ; 25-30 kg/m 2 ; >30 kg/m 2 ). For ARD patients, further controls included use of prednisone, immunosuppressants and biologics. Confounders were selected based on a Direct Acyclic Graph (DAG; www.dagitty.net) (Supplementary Figure 1) . 14 DAG was developed from a priori knowledge to identify a minimum, but sufficient set of covariates to remove confounding from statistical analysis. 15 (Supplementary Figure 2) . The remaining ARD patients (n=898; Table 1 ) and non-ARD individuals (n=197; Supplementary Physically active ARD patients (n=494) were significantly younger (P<.001), and more frequently used prednisone (P<.001) and biologic (P<.001) than inactive (n=404). Active (n=128) and inactive (n=69) non-ARD individuals did not statistically differ in age, sex and BMI (P=.397) (Supplementary Table 2 ). (Figure 4) . To our knowledge, this is the first evidence that a physically active lifestyle may enhance immunogenicity of a vaccine against SARS-CoV-2 in a large cohort of patients with ARD. Vaccination is a major strategy in reducing mortality and morbidity rates for several infectious diseases, 16 including COVID-19. 17 In countries with high capacity of vaccine acquisition and rapid rollouts, both new cases and deaths have been dramatically reduced. However, vaccine efficacy varies between individuals, with particularly low responses found in those with reduced immune function. 18, 19 mRNA vaccines against SARS-CoV-2 can elicit a reduced humoral response in older individuals and in ARD patients, 4-6,20 a finding recently extended to CoronaVac, 9 which has been largely used in highly populated countries, and recently approved for emergency use by WHO. 21 Indeed, previous data from this trial point out to lower SC (70.4 vs. 95.5%) and titers (12.1 vs. 29.7), frequency of NAb positivity (56.3 vs. 79.3%) and neutralization activity (58.7 vs. 64.5%) in ARD patients vs. controls. 9 It becomes clear that the search for adjuvants to enhance vaccine response and improve protection from disease infection is of great clinical importance. Chief amongst these is physical activity, which has been deemed as a behavioral intervention able to boost immune function in different scenarios, thereby potentially serving as an adjuvant to improve vaccine response, including that against SARS-CoV-2. This hypothesis was tested in the present study. Both observational and interventional studies have shown that habitually physically active individuals, or those receiving exercise interventions, present with higher concentration of IgG and IgM following influenza and keyhole limpet haemocyanin (KLH) vaccination. [22] [23] [24] [25] [26] [27] [28] [29] Apart from studies involving older individuals, evidence that physical activity may confer better vaccine responses in those with less functional immunity is lacking. In this regard, our data bring novel evidence that, compared to their inactive counterparts, physically active ARD patients may have higher SC rates, GMT and FI-GMT and a trend to higher neutralizing activity, even after controlling for several covariates, including age, sex, BMI and medications. Of relevance, the positive association of physical activity with GMT (+32%) was diametrically opposite to those of age (-33%), obesity (-30%) and medications (-27 to -48%), which underscores the potential importance of a physically active lifestyle in counteracting factors known to impair immunogenicity. Furthermore, our exploratory analysis suggests that the benefits of being physically active (i.e., meeting the minimum recommended amount of physical activity) on vaccine immunogenicity tends to wane owing to sedentary behavior (i.e., too much sitting), a finding that has been observed in population-based studies for all-cause mortality, 13, 30 and that requires confirmation for vaccines responses. We also observed a direct dose-response relationship between physical activity volume and SC, GMT, and FI-GMT. Although current evidence does not yet provide specific information about how intensity, frequency, duration and type of physical activity influence vaccine responses, 11 the present findings suggest that engaging in at least 150 min/week of moderate-to-vigorous physical activity while avoiding excessive sitting time may enhance immunogenicity to vaccination against SARS-CoV-2, with higher physical activity amounts (≥350 min/week) possibly offering greater benefits. Hypothetically, young healthy adults might be less responsive to the benefits of physical activity on immunogenicity, since the robust response to most vaccinations in this population may mask more subtle effects of exercise, whereas in those with weaker immune function and higher variability, the immunoenhancement effects may be more noticeable. 17 Similar to ARD patients, however, we observed a positive association between physical activity and SC rates and GMT in non-ARD individuals. This suggests the potential applicability of our findings in a more generalized context; nonetheless, these should be validated in a larger cohort of non-immunosuppressed individuals. The mechanisms by which regular physical activity enhance vaccination responses are not fully understood. However, it is known that moderate-to-vigorous physical activity is able to improve immune function, which is reflected in greater antibody or cell-mediated responses to vaccination. 17, 31 Even a single bout of exercise can elicit substantial changes in the immune system. 32 Described as the ''acute-stress induced immunoenhancement hypothesis'', the increases in epinephrine, cortisol, heart rate and blood pressure encompass the acute response to exercise. 33 Alongside these physiological adjustments is the well-stablished leukocytosis response, the transient increase in muscle-secreted inflammatory cytokines, and the exercise-induced muscle damage leading to leukocyte trafficking to the tissue. These orchestrated adjustments have been postulated to stimulate the activation of immune surveillance in anticipation of antigen entry, 31,34 which may be of particular relevance to vaccination. 33 Although the clinical benefit of physical activity on vaccines efficacy is commonly inferred from the quantified antibody, neutralization activity or cell-mediated responses, this postulation finds support in a population-based cohort study, in which moderately-and highly-active individuals were less likely to experience an influenza-coded visit to a physician or emergency department. 35 Whether SARS-CoV-2 vaccine efficacy may be modulated by physical activity and how it occurs remain to be investigated. Our data is strengthened by the large prospective cohort of immunocompromised patients with ARD, the assessment of immunogenicity using both SARS-CoV-2 IgG and NAb, and the robust control for numerous covariates. Limitations include the use of questionnaire to assess physical activity, which is prone to recall bias and overreporting; the cross-sectional assessment of physical activity prior to vaccination, which may not accurately reflect the typical physical activity pattern before the pandemic; 36 lack of estimates of vaccine effectiveness to bridge to the immunogenicity data; short-term assessment of immunogenicity, precluding any firm conclusions on the persistency of the observed responses; lack of assessment of cell-mediated immune responses; observational nature of the study, hampering causative inferences; and the constraint of the results to the vaccine tested in this study. Regarding the latter, it is noteworthy that over 750 million doses of CoronaVac have been administered in more than 40 countries, 37 with a prospective, national-cohort, phase 4 trial showing its excellent safety profile and effectiveness against severe cases and COVID-19-related death. 38 However, this vaccine seems to evoke less protective titer compared to others, a response associated with lower protection from SARS-CoV-2 infection. 39 In addition, assessments of immune persistence of CoronaVac showed that prevalence of seropositivity decreased to 17% following 6 months. 40 These observations underpin the clinical importance of the current findings, which point out to the potential utility of a safe, inexpensive, population-wide strategy (i.e., physical activity) in enhancing CoronaVac immunogenicity in patients with autoimmune disorders. Nonetheless, it is uncertain whether physical activity associates with enhanced responses to other vaccine platforms able to elicit higher protective titer, as a ceiling effect may exist, particularly for heathy individuals. Recent evidence shows that active individuals seem less susceptible to COVID-19related ICU admission and mortality. 41 Now this study suggests that a physical active lifestyle may also enhance SARS-CoV-2 vaccine immunogenicity, a finding of particular relevance for patients with dysfunctional immune system living in countries facing vaccines scarcity, which hampers the immediate administration of additional doses. Our data reinforce the need for a global call for action to delivery physical activity during the COVID-19 pandemic, with emphasis to groups with reduced immune function. RCTs should confirm the efficacy of physical activity to enhance vaccine responses, and to stablish the optimal dose to elicit the greatest benefits. Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination (Indirect ELISA, LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin, Italy). Positivity for NAb was defined as a neutralizing activity ≥ 30% (cPass sVNT Kit, GenScript, Piscataway, USA). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial Exercise and the Regulation of Immune Functions Effects of Regular Physical Activity on the Immune System, Vaccination and Risk of Community-Acquired Infectious Disease in the General Population: Systematic Review and Meta-Analysis World Health Organization 2020 guidelines on physical activity and sedentary behaviour Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women Causal diagrams in systems epidemiology Data, design, and background knowledge in etiologic inference The effects of exercise on vaccination responses: a review of chronic and acute exercise interventions in humans Vaccines in historic evolution and perspective: a narrative of vaccine discoveries Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine World Health Organization, Strategic Advisory Group of Experts (SAGE) on Immunization, SAGE Working Group on COVID-19 Vaccines. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac Cardiovascular exercise intervention improves the primary antibody response to keyhole limpet hemocyanin (KLH) in previously sedentary older adults Higher antibody, but not cell-mediated, responses to vaccination in high physically fit elderly Exercise and psychosocial factors modulate immunity to influenza vaccine in elderly individuals Moderate exercise improves antibody response to influenza immunization in older adults Effect of physical activity on the production of specific antibody in response to the 1998-99 influenza virus vaccine in older adults Influence of age and physical activity on the primary in vivo antibody and T cell-mediated responses in men Cardiovascular Exercise Training Extends Influenza Vaccine Seroprotection in Sedentary Older Adults: The Immune Function Intervention Trial Effects of a Taiji and Qigong intervention on the antibody response to influenza vaccine in older adults Sitting Time, Physical Activity, and Risk of Mortality in Adults Effects of exercise on vaccine-induced immune responses Acute exercise enhancement of pneumococcal vaccination response: A randomised controlled trial of weaker and stronger immune response The acute stressinduced immunoenhancement hypothesis Stress as an endogenous adjuvant: augmentation of the immunization phase of cell-mediated immunity Physical activity and influenza-coded outpatient visits, a population-based cohort study Worldwide Effect of COVID-19 on Physical Activity: A Descriptive Study Effectiveness of an Inactivated SARS-CoV-2 Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Rcommendation for an Emergency Use Listing of COVID-19 Vaccine (Vero Cell), Inactivated Submitted by Sinovac Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination (Indirect ELISA, LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin, Italy) Adjusted risk factors for immunogenicity data in non-autoimmune rheumatic diseases (non-ARD) individuals CIs) with binary data was used for frequency of seroconversion rates of total anti-SARS-Cov-2 S1/S2 IgG (SC) and neutralizing antibodies (NAb) positivity. Tobit regression was used for natural log transformed GMT, FI-GMT and neutralizing activity. *P<.05, **P<.01, ***P<.001. Seroconversion was defined as a positive serology (IgG titer ≥ 15 AU/ml) for anti-SARS-CoV-2 S1/S2 IgG antibodies after vaccination Positivity for NAb was defined as a neutralizing activity ≥ 30% (cPass sVNT Kit The authors are thankful to Marta H. Lopes, Tatiana The authors have no conflict of interests.